William Schultz focuses on appellate and other civil litigation, food and drug law, and administrative and public interest law. Drawing his vast experience in these areas, he represents individuals (including those who have been injured by foods, drugs, and other products), generic and small biotechnology drug companies, a state government, associations, and advocacy organizations before the courts, government agencies, and Congress. Between 1983 and 1996, Mr. Schultz taught Civil Litigation and Food and Drug Law at Georgetown University Law Center.
Before joining Zuckerman Spaeder, Mr. Schultz held the position of Deputy Assistant Attorney General. During his tenure, he supervised all appellate litigation conducted by the U.S. Department of Justice's Civil Division and the Department's lawsuit against the tobacco industry, one of the largest lawsuits ever initiated by the U.S. government. He also served as the Food and Drug Administration's Deputy Commissioner for Policy, overseeing the development of all FDA policies and regulations and FDA legislation, and was Counsel to Representative Henry A. Waxman, Chairman of the House Subcommittee on Health and the Environment, assisting in the development of food and drug and other healthcare legislation. At Public Citizen Litigation Group, where he began his legal career, Mr. Schultz tried and argued cases in federal and state trial and appellate courts, including several cases in the U.S. Supreme Court. Before entering law practice, he clerked for Judge William B. Bryant, U.S. District Court, Washington, DC.
Mr. Schultz has taught Civil Litigation and Food and Drug Law at Georgetown University Law Center.
ARTICLE HIGHLIGHTS
"Hazardous Hucksters," The Washington Post, May 28, 2002 (with Michael R. Taylor).
"The Leaderless F.D.A.," The New York Times, April 17, 2001.
"Tort Law Deference to FDA Regulation of Medical Devices," 88 Geo. L.F. 2119 (2000) (with Michael Green).
"The FDA's Decision to Regulate Tobacco Products," Pace Law Review, vol. 1, no. 1, Fall 1997.
"The Food and Drug Administration's Regulation of Tobacco Products," The New England Journal of Medicine, vol. 335, no. 13, September 26, 1996, pp. 988-994.
"Should Drug Firms Be Allowed to Give Doctors Peer-Reviewied Reprints on Off-Label Uses?" Physicians Weekly, vol. XIII, no. 12, March 25, 1996.
"Some Thoughts on FDA Reform," Tufts CSDD Newsletter, Tufts Center for the Study of Drug Development, vol. 21, no. 1, February 1996.
"We're Not Dragging Our Feet on New Drugs," The Washington Post, April 19, 1995, B9.
"Food, Drugs and Medical Devices," in Changing America: Blueprints for the New Administration (1993).
The Judicial Record of Judge Robert H. Bork (August 1987) (coauthor of book and director of project), reprinted at 9 Cardoza L. Rev. 297 (1987).
"Don't Put the Sick at Further Risk," USA Today (March 24, 1987).
"Public Interest Law with Bread on the Table," ABA Journal (February 1985) (with Ralph Nader).
"Reforming the Civil Division of the Department of Justice", Changing America: Blueprints for a New Administration (1992) (with David Vladeck).
"Why the FDA's De Minimis Interpretation of the Delaney Clause Is a Violation of Law", 7 Journal of the American College of Toxicology 521 (1988).
"The Bitter After-Taste of Saccharin", 40 Food, Drug, Cosmetic Law Journal 66 (Jan. 1985).
"Drugs" in Retreat From Safety (Pantheon Books, 1984).
"United States v. Generix: A Preview," 37 Food, Drug, Cosmetic Law Journal 337 (1982).
"Labels, Bans, and Consumer Preferences," in Banbury Report 6: Product Labeling and Health Risks (Cold Spring Harbor Laboratory, 1980).
The Myth of Swing Voting: An Analysis of Voting Patterns on the Supreme Court, 50 N.Y.U. Law Review 798 (1976) (with Philip K. Howard).